Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

MOLECULAR PREDICTORS OF OUTCOME IN PATIENTS WITH OSTEOSARCOMA

7th Congress of the European Federation of National Associations of Orthopaedics and Traumatology, Lisbon - 4-7 June, 2005



Abstract

Background: A variety of molecular markers related to survival, have been studied in a variety of human neoplasms, particularly in carcinomas, but their significance in osteosarcoma patients is largely unknown. The purpose of this archival study was to determine if there is a correlation between their expression and disease-free and overall survival for patients with osteosarcoma.

Materials and Methods: 93 patients with stage IIB osteosarcomas originating around the knee (distal femur and proximal tibia)were studied. Tumors were evaluated with antibodies to Bcl-2, p53, Fas, Fas L, CD44s, CD44v6, and P-glycoprotein using standard avidinbiotin complex methods. Expression of the various antigens was statisticaly compared to disease-free and overall survival.

Results: Fas (p< 0.05) and Cd44v6 (p< 0.03), were significant and related with the purpose of study; P-glycoprotein was near and the others with no significance.

Conclusions: Fas appears to have a “protective” function in osteosarcoma, probably by allowing tumor cells to proceed through apoptosis pathway to cell death. Although CD44v6, a vascular adhesion molecule, was identified in only 14% of the total cases, its expression correlated with subsequent development of metastases and death (11 of the 13 patients developed pulmonary metastases dying of disease). Although P-glycoprotein did not reach significance, there was a trend toward death from disease in patients expressing it.

Theses abstracts were prepared by Professor Roger Lemaire. Correspondence should be addressed to EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.